UK Markets open in 5 hrs 7 mins

Avadel Pharmaceuticals plc (AVDL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.52+0.36 (+4.41%)
At close: 4:00PM EDT
8.50 -0.02 (-0.23%)
After hours: 07:47PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3N/A
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) 1.30
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 310.80
52-week low 34.95
50-day moving average 38.92
200-day moving average 38.05

Share statistics

Avg vol (3-month) 3574.72k
Avg vol (10-day) 31.27M
Shares outstanding 558.49M
Implied shares outstanding 6N/A
Float 844.78M
% held by insiders 11.07%
% held by institutions 157.78%
Shares short (12 Aug 2021) 43.64M
Short ratio (12 Aug 2021) 413.35
Short % of float (12 Aug 2021) 4N/A
Short % of shares outstanding (12 Aug 2021) 46.21%
Shares short (prior month 14 Jul 2021) 43.89M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-13.03%
Return on equity (ttm)-37.21%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)16.59M
EBITDA -63.92M
Net income avi to common (ttm)-56.01M
Diluted EPS (ttm)-0.10
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)204.26M
Total cash per share (mrq)3.49
Total debt (mrq)143.86M
Total debt/equity (mrq)121.01
Current ratio (mrq)14.17
Book value per share (mrq)2.33

Cash flow statement

Operating cash flow (ttm)-62.88M
Levered free cash flow (ttm)-35.64M